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AbstrACt
Introduction Despite guideline recommendations 
advocating conservative management before 
invasive treatment in intermittent claudication, early 
revascularisation remains widespread in patients with 
favourable anatomy. The aim of the Effect of Disease 
Level on Outcomes of Supervised Exercise in Intermittent 
Claudication Registry is to determine the effect of the 
location of stenosis on the outcomes of supervised 
exercise in patients with intermittent claudication due to 
peripheral arterial disease.
Methods and analysis This multicentre prospective 
cohort study aims to enrol 320 patients in 10 vascular 
centres across the Netherlands. All patients diagnosed 
with intermittent claudication (peripheral arterial disease: 
Fontaine II/Rutherford 1–3), who are considered candidates 
for supervised exercise therapy by their own physicians 
are appropriate to participate. Participants will receive 
standard care, meaning supervised exercise therapy first, 
with endovascular or open revascularisation in case of 
insufficient effect (at the discretion of patient and vascular 
surgeon). For the primary objectives, patients are grouped 
according to anatomical characteristics of disease (aortoiliac, 
femoropopliteal or multilevel disease) as apparent on the 
preferred imaging modality in the participating centre (either 
duplex, CT angiography or magnetic resonance angiography). 
Changes in walking performance (treadmill tests, 6 min walk 
test) and quality of life (QoL; Vascular QoL Questionnaire-6, 
WHO QoL Questionnaire-Bref) will be compared between 
groups, after multivariate adjustment for possible 
confounders. Freedom from revascularisation and major 
adverse cardiovascular disease events, and attainment of the 
treatment goal between anatomical groups will be compared 
using Kaplan-Meier survival curves.
Ethics and dissemination This study has been exempted 
from formal medical ethical approval by the Medical 
Research Ethics Committees United ‘MEC-U’ (W17.071). 
Results are intended for publication in peer-reviewed 
journals and for presentation to stakeholders nationally 
and internationally.
trial registration number NTR7332; Pre-results.
IntroduCtIon
Peripheral arterial disease (PAD) is a 
chronic condition caused by atherosclerotic 
narrowing and blocking of the peripheral 
arteries. Intermittent claudication (IC) is 
the most common manifestation of PAD and 
strengths and limitations of this study
 ► This is the first prospective, longitudinal study link-
ing the outcomes of supervised exercise therapy in 
intermittent claudication to the location and extent 
of the underlying atherosclerotic lesions.
 ► Apart from clinical outcome measures such as free-
dom from intervention, the Effect of Disease Level 
on Outcomes of Supervised Exercise in  Intermittent 
Claudication Registry includes a wide range of func-
tional measures of walking performance and quality 
of life.
 ► Potential participants are approached in 10 vascular 
surgery centres across the Netherlands, ensuring a 
varied patient population and clinical practice reflec-
tive of standard care in the Dutch healthcare system.
 ► The location and extent of stenosis is determined 
using duplex ultrasound scanning in most partic-
ipants; a non-invasive and valid tool, but prone to 
visualisation issues in case of bowel gas or unfa-
vourable body habitus.
 ► Participants with aortoiliac disease and femoropopli-
teal disease are expected to differ regarding several 
clinical characteristics (eg, smoking status, diabetes 
mellitus, body mass index and ankle-brachial index) 
and adjustment for these variables will be performed 
in the analysis, but unmeasured confounding could 
influence the results.
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is marked by exertional discomfort in the leg muscles. 
These symptoms limit walking ability leading to functional 
disability in daily life. Treatment of IC symptoms aims at 
improving walking capacity and thereby health-related 
quality of life (QoL).1 Over the past decade, supervised 
exercise therapy (SET) and endovascular revasculari-
sation (ER) have been shown to be equally effective in 
this regard.2–8 As SET is the non-invasive9 and less costly10 
option, current guidelines recommend SET as primary 
treatment in the management of patients with IC.1 Ideally, 
invasive treatment is saved for patients unresponsive to 
SET, which is the case in approximately 20% of patients 
after 2 years.11 
Clinical practice often deviates from the guidelines, as 
worldwide reimbursement issues and lacking availability 
of adequate SET programmes hamper widespread adop-
tion.12–14 In the Dutch healthcare system, SET is both 
available and reimbursed.15 Nevertheless, a significant 
proportion of patients receive early ER in the Nether-
lands.11 Some vascular professionals argue that in certain 
subsets of patients SET will probably fail and a lower 
threshold to initiate invasive treatment is warranted. 
Divergent reasons, oftentimes contradictory, are cited 
considering factors such as age, comorbidity, (vascular) 
medical history or personality traits. However, these 
claims are mostly practice-based as the current literature 
provides no grounds to discern a subset of patients who 
will be unresponsive to SET.
One of the main arguments for early revascularisa-
tion is the location and extent of the atherosclerotic 
lesion. Excellent patency rates and procedural results 
of aortoiliac ER in clinical trials prompt some clinicians 
to employ more liberal indications to intervene first in 
these patients.16 However, three randomised controlled 
trials (RCTs) compared SET with ER for patients with IC 
due to an iliac artery obstruction and found no important 
differences regarding walking distance or QoL.3 5 17 None-
theless, the idea that in a real-world setting individuals 
with proximal disease might experience less improve-
ment after exercise training compared with patients with 
distal lesions remains widespread. Most studies exam-
ining the functional outcomes of patients after following 
a SET programme do not specify the anatomic distribu-
tion of disease. Greenhalgh et al18 reported the outcome 
of SET for aortoiliac and femoropopliteal disease sepa-
rately, from a trial comparing SET with ER. No formal 
comparison between outcomes in both anatomic groups 
was made and the sample size was small, but no apparent 
difference in effectiveness can be noted. The premise 
that the outcomes of SET depend on anatomic location 
and extent of disease is not based on empirical evidence.
Based on the available evidence an inferior effect of 
SET due to lesion location cannot be assumed. There-
fore, the primary aim of this study is to determine the 
effect of the location of stenosis (femoropopliteal vs 
aortoiliac vs multilevel disease) on the outcomes of SET 
in patients with IC. To this end, the functional and clin-
ical outcomes from ‘real  world’ subjects treated with SET 
will be recorded, applying a minimal amount of subject 
selection criteria.
research objectives
Primary objective
The aim of the Effect of Disease Level on Outcomes 
of Supervised Exercise in  Intermittent Claudication 
(ELECT) Registry is to determine the effect of the loca-
tion of stenosis on the outcomes of SET in patients with 
IC (PAD; Fontaine II, Rutherford 1–3), by recording the 
clinical outcomes from consecutive ‘real world’ subjects 
treated with SET. The primary objective is to determine 
the outcomes of SET in patients with aortoiliac disease 
compared with femoropopliteal disease with regard to 
the following measures:
1. The primary end point is change in maximum and 
functional walking distance on a standardised tread-
mill test after 3, 6 and 12 months of SET.
2. Change in 6-minute walk test (6MWT) performance 
after 3, 6 and 12 months of SET.
3. Change in Vascular QoL Questionnaire-6 (Vas-
cuQoL-6) and WHO QoL Questionnaire-Bref (WHO-
QoL-BREF) outcomes at 3 and 6 months, and 1, 2 and 
5 years, follow-up.
4. Freedom from vascular interventions for the lower-ex-
tremities, at 6 months and 1, 2, and 5 years, follow-up.
5. Achievement of the main treatment goal, as drafted by 
the physical therapist and patient at the start of the 
SET programme, and indicated in the feedback letter 
after 3, 6 and 12 months of SET.
6. Freedom from major adverse cardiovascular events at 
1, 2 and 5 years, follow-up.
Secondary objectives
This study will also determine the outcomes of SET in 
patients with aortoiliac disease compared with femoro-
popliteal disease, multilevel disease and patients without 
aortoiliac and femoropopliteal disease, with regard to the 
above-mentioned measures.
The ELECT Registry dataset will furthermore be used 
to investigate the effect of SET on the overall IC popula-
tion regarding the following objectives:
 ► To determine whether several baseline clinical char-
acteristics and functional measures are predictive 
of changes in walking performance and clinical 
outcomes of SET.
 ► To determine whether specific personality traits 
(extraversion, neuroticism, conscientiousness, 
self-control, barrier self-efficacy, anxiety, depression 
and optimism) measured at baseline are predictive of 
the clinical outcomes of SET.
 ► To determine the change in barrier self-efficacy after 
3, 6 and 12 months of SET.
MEthods
study design and setting
The ELECT Registry is a multicentre prospective cohort 
study initiated from the vascular surgery department of 
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the Catharina Hospital in Eindhoven, the Netherlands. 
All patients diagnosed with IC (PAD; Fontaine II/Ruther-
ford 1–3), who are considered candidates for SET by their 
own physicians, and meet the inclusion criteria (box 1), 
are eligible. Recruitment will take place in 10 vascular 
surgery departments throughout the Netherlands: the 
Catharina Hospital, Amphia Hospital, Elisabeth Twee 
Steden Hospital, Albert Schweitzer Hospital, Rijnstate 
Hospital, Medical Spectrum Twente, University Medical 
Centre Utrecht, Amsterdam University Medical Centre, 
Máxima Medical Centre and VieCuri Medical Centre. 
In these centres, the treating vascular surgeon will seek 
verbal consent from eligible patients to be approached 
by a research coordinator. Candidates will subsequently 
receive written information on the study, inviting them to 
participate, with two consent forms and a self-addressed 
envelope. These patients will be contacted by telephone 
by the coordinating investigator within 1 week after their 
visit to the vascular surgeon to establish formal agree-
ment to participate in the study. If the patient agrees to 
participate, he/she will sign the consent forms and will 
send both forms in the self-addressed envelope to the 
coordinating investigator. After receiving the two consent 
forms, the coordinating investigator will sign both 
forms and return one version to the patient. To ensure 
adequate data collection, the participating centres are 
recommended to schedule the subjects’ follow-up visit(s) 
based on the current standard of care as prescribed by 
the Dutch guidelines, which is at 3– 6 months. At this 
moment, the decision to either continue conservative 
management, or treat invasively (endovascular or open 
revascularisation) is generally made.
treatment of subjects
All patients will receive standard cardiovascular risk 
management by their physician; including smoking cessa-
tion advice, statin therapy and platelet inhibitors, as expli-
cated in the multidisciplinary guidelines.1 Furthermore, 
patients will receive a standard regimen of SET, which 
entails exercise and lifestyle coaching. SET is provided 
by qualified physical therapists according to usual prac-
tice (specified in the physical therapy guidelines).19 All 
therapists are affiliated with ClaudicatioNet, a Dutch 
network of physical therapists specialised in SET with life-
style guidance. This guarantees uniform quality of care 
through mandatory training courses in practice guide-
lines, motivational interviewing skills and other IC-rele-
vant topics.15 A typical SET programme contains up to 
37 individual sessions, spanning 3–12 months. A session 
consists of 30 min of treadmill-based or track-based exer-
cise. The initial workload of the treadmill is set to a speed 
and grade that elicits claudication symptoms within 
3–5 min. Patients are asked to continue to walk at this 
workload until they experience claudication of moderate 
severity. A brief period of rest permits symptoms to 
resolve. An exercise-rest-exercise cycle is repeated several 
times. Such a programme requires intense monitoring of 
patients aimed at increasing workload by adjusting tread-
mill grade or speed (or both).15 19 This will generally be 
performed at least three times a week in the first 4 weeks 
and one to two times a week for the next 8 weeks.15 After 
that, there is a maintenance phase during which SET will 
be given for one to two times a month. As stated in their 
guidelines, the physical therapist records several outcome 
measurements at 3, 6, 9 and 12 months follow-up.19 To 
investigate the study’s objectives, data obtained in this 
standard follow-up routine will be recorded prospectively.
Assessments
This study will use diagnostic and outcome measures 
that are recorded as part of the usual clinical practice, 
supplemented by several questionnaires, all specified 
below. Outcomes are collected from the standardised 
feedback letter sent by physical therapists (see online 
supplementary file 1) and the patient’s hospital elec-
tronic health record. Table 1 provides an overview of all 
study assessments.
Baseline patient characteristics
Participants’ sociodemographic data (age, sex), medical 
history and comorbidity (chronic obstructive pulmo-
nary disease, lower-extremity musculoskeletal disease, 
diabetes mellitus, dyslipidaemia, hypertension, kidney 
disease, cerebrovascular disease, ischaemic heart disease, 
box 1 Eligibility criteria.
Inclusion criteria
 ► IC due to unilateral or bilateral PAD (Fontaine II, Rutherford 1–3).
 ► Resting ABI<0.9 (or TBI<0.7) or drop in ABI>0.15 after exercise.
 ► Candidate for SET as a primary treatment, at the discretion of the 
treating vascular surgeon.
 ► Recent or planned imaging of at least the aortoiliac and femoropop-
liteal tract (within 6 months of SET initiation, but prior to possible 
vascular intervention): either colour duplex scanning or CTA or MRA.
 ► Signed informed consent form.
Exclusion criteria
 ► Advanced PAD beyond IC (ie, ischaemic rest pain and/or ulcers, 
Fontaine>II, Rutherford 4–6).
 ► High probability of non-adherence to physician’s, or physical thera-
pist’s follow-up requirements (eg, due to lack of motivation or past 
compliance issues).
 ► Current participation in a concurrent trial that may confound study 
results.
 ► Vascular intervention as primary treatment, at the discretion of the 
treating vascular surgeon.
 ► Prior SET, performed in accordance with the guidelines of the Dutch 
Society for Physical Therapists, in the previous 12 months.
 ► Prior revascularisation in the lower  extremities in the previous 
12 months.
 ► Neurogenic/venous/orthopaedic claudication more dominant than 
arterial claudication complaints.
ABI, ankle-brachial index; CTA, computed tomographic angiography; IC, 
intermittent claudication; MRA, magnetic resonance angiography; PAD, 
peripheral arterial disease; SET, supervised exercise therapy; TBI, toe-brachial 
index.
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heart failure), cardiovascular risk factors (body mass 
index (BMI), smoking status), prior (cardio-)vascular 
interventions (coronary artery bypass grafting, percu-
taneous coronary intervention, open or endovascular 
abdominal aortic aneurysm repair, lower-extremity revas-
cularisation) and prior SET will be extracted from the 
electronic health records of the hospital and/or physical 
therapist.
Vascular imaging and laboratory assessment
Resting and postexercise ankle-brachial index (ABI) 
determinations in both legs are performed by trained 
vascular technicians in all participating centres using 
handheld Doppler instruments, as part of the routine 
work-up. The ABI is defined as the ratio between the 
highest systolic pressure of the dorsal pedal or posterior 
tibial artery, and the highest of the left or right brachial 
pressure. To determine the anatomic location and extent 
of atherosclerotic disease, the ELECT Registry uses the 
preferred vascular imaging modality of the treating 
vascular surgeon, performed ≤3 months before or after 
inclusion.
In case of magnetic resonance angiography (MRA) or 
CT angiography (CTA), the scan is evaluated and inter-
preted by experienced radiologists in the participating 
centres as per usual care. A stenosis of >50% on MRA 
or CTA is considered significant. The reported accuracy 
of CTA and MRA to detect significant arterial stenosis 
in PAD is >90%.1 Duplex ultrasound scanning (DUS) is 
carried out by accredited vascular technicians to deter-
mine the location, extent and severity of the atheroscle-
rotic lesions. A lesion is considered significant if either 
a peak systolic velocity ratio of ≥2.5, or an end-diastolic 
velocity of ≥0.6 m/s is observed, or if an occlusion is visu-
alised (no flow). The reported sensitivity and specificity 
of DUS in patients with PAD to detect significant arterial 
stenoses is over 80% and 90%, respectively.1
Table 1 Study timeline and assessments
Baseline
T0 3 monthst1 6 monthst2 12 monthst3 2 yearst4 5 yearst5
Baseline characteristics
  Sociodemographic data X
  Cardiovascular risk factors X
  Comorbidity X
  Medical history X
  Prior vascular interventions X
  Vascular laboratory assessment X
  Vascular imaging (DUS/CTA/MRA) X* X*
Outcome measures
  Treadmill test† X X X X
  6MWT† X X X X
  WHOQoL-BREF X X X X
  Barrier self-efficacy scale X X X X
  VascuQoL-6 X X X X X X
  Smoking status X X X X X X
  Attainment of treatment goal X X X X X
  Freedom from vascular intervention X X X X X
  Major adverse cardiovascular events X X X X X
Personality traits
  Big Five Inventory X
  HADS X
  Brief Self-Control Score X
  Life Orientation Test-Revised X
  Barrier Self-Efficacy Scale X X X X
*Imaging is eligible when performed ≤3 months before or after inclusion.
†The treadmill test and 6MWT are performed on different days, thus two visits are necessary per time point to collect all outcome measures.
6MWT, 6 min walk test; CTA, CT angiography; DUS, duplex ultrasound scanning; HADS, Hospital Anxiety and Depression Scale; IC, 
intermittent claudication; MRA, magnetic resonance angiography; VascuQoL-6, Vascular Quality of Life Questionnaire-6; WHOQoL-BREF, 
WHO Quality of Life Questionnaire-Bref.
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To categorise all participants according to anatomic 
location a team of three physicians (one vascular surgeon, 
two PhD candidates) will independently assess the DUS 
reports and readings and/or MRA or CTA scans and 
radiologist reports. Participants will be divided into four 
groups:
1. Aortoiliac lesions, containing patients with significant 
stenoses or occlusions in the common iliac artery, ex-
ternal iliac artery and/or internal iliac artery.
2. Femoropopliteal lesions, containing patients with sig-
nificant stenoses or occlusions in the common femo-
ral artery, superficial femoral artery and/or popliteal 
artery.
3. Multilevel disease, containing patients with significant 
stenoses at both the aortoiliac and femoropopliteal lev-
el.
4. Rest group, containing patients with no significant 
stenoses in the aortoiliac and femoropopliteal tract. 
Notably, undetected infrageniculate disease distal-
ly from the area scanned with DUS may exist in this 
group. This category is expected to contain some 5% 
of patients meeting the eligibility criteria based on a 
retrospective exploratory analysis of a consecutive co-
hort of patients from the vascular surgery outpatient 
clinic in the initiating centre.
The same three physicians will also assign a Trans-
atlantic Inter-Society Consensus for the Management 
of PAD (TASC) classification for each arterial trajectory 
with a significant lesion. Notably, the inter-observer agree-
ment for rating TASC classifications is poor.20 21 Thus, 
disagreement is solved by discussion and consultation of 
a fourth observer (vascular surgeon).
Walking performance
Treadmill-measured walking distance
The maximum walking distance (MWD) and functional 
walking distance (FWD) will be recorded for each patient 
at baseline, 3, 6 and 12 months follow-up, using a stan-
dardised treadmill test. The MWD is defined as the 
walking distance where intolerable claudication pain 
forces a patient to stop. An alternative term for MWD is 
‘absolute claudication distance’. The FWD is defined as 
the distance at which the patient prefers to stop walking 
because of pain. Notably, this is a different measure from 
the ‘pain-free walking distance’ or ‘initial claudication 
distance’ commonly used in PAD literature. The FWD 
was previously found to be reliable (intraclass correlation 
coefficient 0.959) and probably a better reflection of func-
tional impairment compared with the initial claudication 
distance.22 Walking distances are determined by a stan-
dardised progressive treadmill test (ie, Gardner-Skinner 
protocol23) with a constant speed of 3.2 km/hour starting 
with 0% incline, increasing every 2 min by 2%. The 
maximum incline is 10%, and the maximum duration 
of the test is 30 min, resulting in a maximum distance of 
1600 m. The test protocol is advised by the Dutch physical 
therapy guidelines.19 ClaudicatioNet therapists are taught 
to offer verbal encouragement and coaching during 
testing, but this was not standardised in this study.
6-Minute walk test
To assess walking performance in a setting more resem-
bling daily life, participants will perform the 6MWT at 
baseline, 3, 6 and 12 months follow-up. Physical therapists 
are instructed to perform the treadmill test and 6MWT 
on different days. The 6MWT records the total distance 
an individual is able to walk over a total of 6 min on a 
hard, flat surface. Participants traverse back and forth 
along a marked walkway. They are allowed to self-pace 
and rest as needed, while timing continues up to 6 min. 
The 6MWT has been validated, shown to be responsive to 
treatment, and is predictive of mortality and mobility loss 
in a PAD population.24
Quality of life
Two questionnaires are used in the ELECT Registry 
to investigate the effect of treatment on QoL. The 
VascuQoL-6 is a valid and responsive instrument for the 
assessment of health-related QoL in PAD.25 It is a short-
ened version of the VascuQoL-25 and contains questions 
relating to the patient’s activities, symptoms, pain and 
emotional and social well-being. Answers are recorded on 
a 4-point scale and added up, resulting in a total score 
between 6 and 24. Higher scores indicate better health-re-
lated QoL. The ELECT Registry uses the Dutch version of 
the VascuQoL-6.
The WHOQoL questionnaire provides a generic assess-
ment of QoL.26 27 The abbreviated version of this tool 
(WHOQoL-BREF) is used in this registry and was previ-
ously found to be valid and reliable.27 It contains ques-
tions on four domains, each scored on a 5-point Likert 
scale: physical health, psychological health, social rela-
tionships and environment. Two additional questions 
assess the subject’s overall QoL and general health. 
Domain scores are obtained by averaging the scores from 
the individual questions and subsequent rescaling to a 
0–100 scale, where higher scores represent a better QoL.
Success of conservative management
Arguably, a successful conservative treatment eliminates 
the need for invasive therapies. Thus, success of SET 
is objectified by freedom from vascular interventions, 
defined as either PTA (with or without stent), bypass, 
endarterectomy or major amputation of the lower extrem-
ities at 6 months, and 1, 2 and 5 years, follow-up.
The decision to intervene is influenced by the risk-ben-
efit ratio of the patient’s lesion and general health status, 
as well as the preferences of the treating vascular surgeon 
and patient. Thus, freedom from intervention is only a 
partial reflection of treatment success. To better capture 
patient satisfaction with treatment the attainment of the 
main treatment goal is recorded. At the start of each SET 
programme each patient determines the main treatment 
goal in conjunction with his or her physical therapist. This 
is recorded in an open text field at the start of treatment, 
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with no restrictions with regard to the domain or measure 
it applies to. Satisfactory achievement of this goal (‘yes’ 
or ‘no’) and the (im)probability of further improvement 
with SET (‘yes’ or ‘no’) are followed-up at 3, 6 and 12 
months and indicated in the standard feedback letter to 
the vascular surgeon (see online supplementary file 1).
Cardiovascular mortality and morbidity
The incidence of major adverse cardiovascular events 
(MACE) at 1, 2 and 5 years follow-up. Events consid-
ered are atherosclerotic cardiovascular death, non-fatal 
myocardial infarction and non-fatal stroke (three-compo-
nent MACE), recorded from hospital records.
Psychological assessments
The five self-report questionnaires described below assess 
personality traits, emotional symptoms and barrier self-ef-
ficacy. Missing data, if not completely at random, will be 
imputed by means of multiple imputation methodology 
to minimise bias.28
Big Five Inventory
The Big Five Inventory (BFI)29 consists of 44 items 
regarding statements of characteristics associated with 
five personality traits, which are openness to experiences, 
agreeableness, extraversion, neuroticism and conscien-
tiousness. This study will focus on the last three traits. Every 
item starts with "I see myself as someone who…" and items 
are rated on a 5-point Likert scale (1=disagree strongly, 
5=agree strongly). The BFI has a high test-retest reliability 
with intraclass correlation coefficients ranging from 0.93 
to 0.96.30 A validated Dutch translation31 is used in this 
study, with satisfactory reliability for measuring the indi-
vidual traits, with Cronbach’s α ranging among traits 
from 0.73 to 0.86 (α >0.7 is a sign of good reliability). The 
scores will be analysed as continuous and as categorical 
variables. Because there are no official cut-off scores avail-
able, the median scores from the current sample will be 
used as cut-off points to translate scores into low and high 
on a specific trait (‘low’<median≥‘high’).
Hospital Anxiety and Depression Scale
The Hospital Anxiety and Depression Scale (HADS) is a 
14-item self-report screening scale which is used to indi-
cate the possible presence of anxiety and/or depressive 
symptoms.32 The scale includes seven items on anxiety 
and seven items on depression, both with a score ranging 
from 0 to 21. The total score is classified into no anxiety 
or depression disorder (≤7), possible disorder (8-10) 
and probable disorder (≥11). The Dutch translation of 
the HADS33 used in the ELECT Registry is validated in 
multiple populations. The internal consistency (Cron-
bach's α ranged from 0.71 to 0.90) and the test-retest 
stability (Pearson's correlation coefficient=0.91) are high.
Brief self-control score
The brief self-control score34 is used to determine self-con-
trol in which a higher score is associated with higher 
self-control. It consists of 13 items rated on a 5-point 
Likert scale (1=disagree strongly, 5=agree strongly) with a 
maximum score of 54. This brief scale has a good test-re-
test reliability with a coefficient of 0.87. A validated Dutch 
translation35 with high internal consistency (Cronbach's 
α=0.80) will be used.
Life orientation test-revised
The life orientation test-revised36 measures optimism 
by means of 10 items, including four ‘filler’ items 
which do not contribute to the total score. The items 
are rated on a 5-point Likert scale (0=disagree strongly, 
4=agree strongly). The total score ranges between 0 and 
24 and a higher total score is associated with a higher level 
of optimism. This revised test has a satisfactory test-retest 
reliability of 0.60–0.68. The validated Dutch translation,37 
with moderate-to-high internal consistency (Cronbach's 
α ranging from 0.58 to 0.80), is used.
Barrier self-efficacy scale
The barrier self-efficacy scale (BSES)38 consists of 13 items 
describing the possibility that one would exercise despite 
the presence of possible barriers, such as bad weather or 
lack of interest. The inventors of the BSES determined 
the barriers by attributive analysis of participants’ argu-
ments for discontinuing exercise programmes. Partici-
pants indicate their degree of confidence for each item 
on a 0% (no confidence at all) to 100% (complete confi-
dence) scale. The mean percentage of all items comprises 
the total score, in which a higher score is associated with 
higher barrier self-efficacy. This study uses a validated 
Dutch translation39 in which one question ("My work 
schedule conflicted with my exercise session") is left out 
because this would not be relevant to the majority of our 
study population. The internal consistency of the Dutch 
scale is high (Cronbach's α=0.84) and has a satisfactory 
test-retest stability with an intraclass correlation coeffi-
cient of 0.63.
sample size
We hypothesise that there will be no clinically relevant 
difference in changes in maximum walking distance 
between subjects with aortoiliac and femoropopliteal 
disease after 6 months. Analogous to previous trials in 
this population, we would consider a mean difference of 
150 m change in walking distance between groups to be 
clinically relevant (SD of 300 m).40 41 To exclude a differ-
ence in means of 150 m with an α of 0.01, a power of 0.80 
(β of 0.2), 96 patients are needed per arterial disease level 
group. The ELECT Registry primarily aims to compare 
patients with single-level disease (aortoiliac vs femoro-
popliteal). Based on a retrospective analysis of consecu-
tive patients with IC in our hospital, this will be the case 
in some 75% of the patients. Thus, for the primary anal-
ysis the required sample size amounts to a total of 256 
patients ((1/0.75)×(96+96)). Assuming a conservative 
drop-out rate of 20%, 320 subjects are required to investi-
gate the primary objective.
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statistical analysis
Categorical variables at baseline will be presented as 
numbers with percentages. Continuous variables as 
means±SD if normally distributed, or as medians with 
interquartile ranges in case of a skewed distribution. 
Participants will be divided into four groups based on 
anatomical characteristics of disease, as apparent on 
the preferential imaging modality of the participating 
centre (either DUS, CTA or MRA). Groups are defined as 
follows: aortoiliac disease, femoropopliteal disease, multi-
level disease or rest group. The primary comparison of 
interest is aortoiliac versus femoropopliteal disease.
Changes in walking distances (treadmill tests, 6MWT) 
and QoL (VascuQoL-6, WHOQoL-BREF) will be 
compared between groups, after multivariate adjustment. 
Adjustment of these measures for possible confounding 
variables will be performed using a general linear model 
with anatomical group as the independent variable. 
Covariates used for this adjustment are selected using 
univariate analysis (inclusion criteria p<0.2). A strin-
gent significance level of 0.01 will be used to account for 
multiple comparisons. Freedom from revascularisation, 
freedom from adverse cardiovascular disease events and 
attainment of the main treatment goal between groups 
will be compared using Kaplan-Meier survival curves and 
log rank tests. Cox proportional hazard analysis will be 
performed to adjust for the above-mentioned possible 
confounders.
Analysis for the remainder of secondary objectives 
is performed on the overall population (regardless of 
lesion location). Multivariable logistic regression will be 
used to determine the impact of several patient charac-
teristics (eg, age, sex, extent of atherosclerotic disease, 
comorbidity, history of cardiovascular disease and 
previous lower-extremity interventions) on success of 
conservative management. Associations between base-
line personality traits and SET-related outcomes (walking 
distance, 6MWT, QoL and freedom from interventions), 
defined as change-from-baseline scores at follow-up, will 
be determined. For categorised BFI traits this will be anal-
ysed with unpaired t-tests (or Mann-Whitney U test in case 
of non-normal distribution) for continuous outcomes 
and Χ2 or Fisher’s exact tests for categorical outcomes. 
Multiple linear regression is performed with person-
ality traits as independent variables and the SET-related 
outcomes as dependent variables. A hierarchical series of 
three models with increasing covariate adjustment will be 
used. In model I, age and sex are included as covariates. 
In model II, secondary invasive treatment (if applicable) 
is added. Finally, in model III, the HADS score is added 
in order to correct for possible symptoms of anxiety and/
or depression. To analyse the change in self-efficacy at 3, 
6 and 12 months follow-up, a linear mixed model will be 
used.
data storage and retention
All data will be handled in accordance with local regula-
tions and privacy laws in an anonymised dataset. Physical 
data will be anonymised and stored accessible only by the 
research team, digital data will be secured using dedi-
cated data management software ‘Research Manager’ (de 
Research Manager, Deventer, the Netherlands). After the 
last participant’s final follow-up moment, all data will be 
stored for a minimum of 15 years.
Ethics and dissemination
This trial does not hamper routine vascular surgery 
or physical therapy treatment for the participants. 
Furthermore, it mainly records diagnostic and outcome 
measures that are performed as part of the usual clinical 
routine, supplemented by several short, non-intrusive 
questionnaires. Therefore, the ELECT Registry has been 
exempted from formal medical ethical approval by the 
Medical Research Ethics Committees United ‘MEC-U’ 
(reference number W17.071). Nonetheless, privacy laws 
require that each subject must authorise the treating 
physician(s), therapists and institutions to release their 
medical information. Each subject must therefore sign a 
patient informed consent form before any data can be 
sent to the coordinating centre. The results are intended 
for publication in peer-reviewed journals and for presen-
tation to stakeholders nationally and internationally.
Patients and public involvement
Patients and public were not explicitly involved in the 
design or conduct of this study. All participants will be 
informed of the results of the ELECT Registry through 
post or email.
dIsCussIon
The ELECT Registry will link anatomical characteristics 
of atherosclerotic disease to the functional and clinical 
outcomes of a SET-first management strategy in IC. This 
prospective observational study will thus primarily offer 
insight in the effect of lesion location on the outcomes 
of SET. It will produce novel results as most previously 
published research on SET as primary treatment either 
does not specify the location of the stenosis, does not 
include all lesions in its study design or does not include 
functional outcome measures. By including a diverse 
range of vascular surgery centres throughout the Nether-
lands, the study will feature a heterogenous patient popu-
lation closely resembling real-world practice.
The dataset from this study will secondarily be used to 
identify predictors of treatment outcome from various 
functional and clinical variables. Previously published 
research aimed to investigate the effect of various patient 
characteristics on outcomes of conservative management 
in IC.42–44 However, this is the first study to include infor-
mation on extent and location of PAD in such analysis. 
Moreover, the ELECT Registry will include a multitude 
of functional and clinical outcomes at both baseline and 
follow-up. The results will facilitate the development of 
a management strategy more tailored to the individual 
patient with IC.
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The ELECT Registry is an observational study and thus 
prone to several validity issues. Mainly, included patients 
in the different lesion location groups are expected to 
differ regarding several clinical characteristics. Indeed, 
van Zitteren et al45 and Aboyans et al46 previously found 
differences in smoking status, diabetes mellitus, BMI 
and ABI between proximal and distal disease. The influ-
ence of these potential confounders is addressed in the 
study protocol by applying multivariate regression anal-
ysis. Despite this covariate adjustment, unmeasured 
confounding could influence the results. For instance, 
intensity of exercise during SET sessions is not recorded, 
nor daily life physical activity levels of patients. Further-
more, DUS is a non-invasive and valid tool to assess loca-
tion and extent of stenosis in PAD, but has its limitations. 
Namely, visualisation of the iliac vessels can be limited due 
to body habitus and/or bowel gas, possibly introducing 
bias in the study design.
ConClusIon
The ELECT Registry, a multicentre prospective cohort 
study, will produce a dataset linking the functional and 
clinical outcomes of SET in IC to the location and extent 
of the atherosclerotic lesions. The results from this 
real-world cohort will inform clinical practice, working 
towards a more tailored management of IC patients.
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